Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia

被引:28
|
作者
Achtyes, Eric [1 ,2 ]
Simmons, Adam [3 ]
Skabeev, Anna [3 ]
Levy, Nikki [3 ]
Jiang, Ying [3 ]
Marcy, Patricia [4 ]
Weiden, Peter J. [3 ]
机构
[1] Cherry Hlth, Grand Rapids, MI USA
[2] Michigan State Univ, Coll Human Med, Grand Rapids, MI 49503 USA
[3] Alkermes Inc, Waltham, MA USA
[4] Northwell Hlth Syst, Vanguard Res Grp, Manhasset, NY USA
来源
BMC PSYCHIATRY | 2018年 / 18卷
关键词
Adherence; Antipsychotics; Weight; Side effects; PSYCHIATRY WFSBP GUIDELINES; BIOLOGICAL TREATMENT; ANTIPSYCHOTIC-DRUGS; REPORTED OUTCOMES; WORLD FEDERATION; UPDATE; 2012; MANAGEMENT; SOCIETIES;
D O I
10.1186/s12888-018-1856-y
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Despite the availability of numerous antipsychotic medications, many patients with schizophrenia continue to experience side effects that contribute to the overall burden of the illness. The present survey of patients with schizophrenia and schizoaffective disorder aimed to assess patient attitudes toward antipsychotic treatment, and understand key factors about willingness to try a new medication. Methods: A cross-sectional survey was administered to 250 patients with a primary clinical diagnosis of a schizophrenia spectrum disorder across five outpatient clinics in the United States. The survey included self-reported gender, age, weight, and height, and questions about the importance of efficacy and side effects on the decision to take a prescribed antipsychotic medication. Results: Patients rated efficacy and side effects as important attributes of antipsychotic treatment, with 93.6% and 83.6% of patients listing these as "very" or the "most" important factors in taking prescribed medication. A total of 87.6% of respondents identified the ability to think more clearly as an important property of their medication. Patients identified weight gain, physical restlessness, and somnolence as important side effects of current treatments ("very" or "most" important by 61.6%, 60.8%, and 58.8%, respectively). When asked about willingness to change antipsychotic medication, anticipated weight gain had a negative influence on willingness to try the new treatment, with 22.0% declining to try a medication that would lead to weight gain of 2.7-4.5 kg (6-10 lb), 34.0% declining for anticipated weight gain of 5.0-9.1 kg (11-20 lb), and 52.4% declining for anticipated weight gain greater than 9 kg (20 lbs). Conclusion: Patients living with schizophrenia spectrum disorders are influenced by many factors when considering whether to take their medication, including efficacy and side effects. It is important for clinicians to assess specific patient concerns to develop a comprehensive treatment plan that maximizes adherence to the prescribed therapy.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Sociodemographic profile of ambulatory patients with schizophrenia: Survey on functional and pragmatic factors
    Bobes, J.
    Arango, C.
    Fillat, O.
    SCHIZOPHRENIA BULLETIN, 2007, 33 (02) : 227 - 227
  • [22] Improved side-effect profile for interferon therapy in MS patients using autoinjectors
    Rosenberg, JH
    NEUROLOGY, 2001, 56 (08) : A362 - A362
  • [23] Survey of antipsychotic medications prescribed for concomitant use by schizophrenia patients being treated with olanzapine
    Kugimiya, R.
    Endo, T.
    Hashimoto, C.
    Ogino, S.
    Miyake, N.
    Utagawa, I.
    Sasuga, Y.
    Kubota, H.
    Takagi, H.
    Miyamoto, S.
    Yamaguchi, N.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 153 - 153
  • [24] Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacy
    Kauf, Teresa L.
    Yang, Jui-Chen
    Kimball, Alexa B.
    Sundaram, Murali
    Bao, Yanjun
    Okun, Martin
    Mulani, Parvez
    Hauber, A. Brett
    Johnson, F. Reed
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2015, 26 (06) : 507 - 513
  • [25] Evaluation of the Biodistribution, Efficacy, and Side-Effect Profile of Deflazacort, Prednisolone and Vamorolone in a DMD Mouse Model
    Liu, Grace
    Lipari, Phil
    Mollin, Anna
    Jung, Stephen
    Teplova, Irina
    Ma, Marcia
    Li, Wencheng
    Ying, Lanqing
    Yeh, Shirley
    Narasimhan, Jana
    Trifillis, Panayiota
    Leonardi, Efthimia
    Welch, Ellen
    Voronin, Gregory
    Dong, Elaine
    Mastrandrea, Nicholas
    Blaize, Jonathan
    Weetall, Marla
    NEUROLOGY, 2023, 100 (17)
  • [26] Effect of living with patients on caregiver burden of individual with schizophrenia in China
    Zhou, Yanling
    Ning, Yuping
    Rosenheck, Robert
    Sun, Bin
    Zhang, Jie
    Ou, Yufen
    He, Hongbo
    PSYCHIATRY RESEARCH, 2016, 245 : 230 - 237
  • [27] JARGON APHASIA VS SCHIZOPHRENIA, ANTI-PSYCHOTIC MEDICATION WITH DYSPROSODY AS A SIDE-EFFECT - A CASE-STUDY
    CHEVREAUXBOURGEOIS, P
    VEROFF, AE
    ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 1983, 64 (10): : 503 - 503
  • [28] EFFECT OF TYPICAL ANTIPSYCHOTIC MEDICATIONS AND CLOZAPINE ON SMOOTH PURSUIT PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA
    FRIEDMAN, L
    JESBERGER, JA
    MELTZER, HY
    PSYCHIATRY RESEARCH, 1992, 41 (01) : 25 - 36
  • [29] INITIATION OF LONG-TERM PHARMACOTHERAPY IN SCHIZOPHRENIA - DOSAGE AND SIDE-EFFECT COMPARISONS BETWEEN ORAL AND DEPOT FLUPHENAZINE
    SCHOOLER, NR
    LEVINE, J
    PHARMAKOPSYCHIATRIE NEURO-PSYCHOPHARMAKOLOGIE, 1976, 9 (04): : 159 - +
  • [30] A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia
    Marco DiBonaventura
    Susan Gabriel
    Leon Dupclay
    Shaloo Gupta
    Edward Kim
    BMC Psychiatry, 12